Toxicology News and Research

Latest Toxicology News and Research

Best practices for assessing toxicity during drug discovery process

Ingenuity® Systems, the leading provider of information solutions for life science researchers, today announced the release of the white paper, "Best Practices for Assessing Toxicity throughout the Drug Discovery Process: Toxicogenomics." The white paper is based on input from industry experts and shows how multidisciplinary toxicology teams in drug discovery can leverage toxicogenomics and IPA® for improved predictive toxicology and mechanistic toxicity analysis.

17 Aug 2010

IBCERCC to improve existing research programs for breast cancer

A newly formed advisory committee will develop and coordinate a strategic federal research agenda on environmental and genetic factors related to breast cancer. The 19 member Interagency Breast Cancer and Environmental Research Coordinating Committee was established by the National Institute of Environmental Health Sciences, in collaboration with the National Cancer Institute, to review all breast cancer research efforts conducted or supported by federal agencies.

17 Aug 2010

Researchers develop screening tool to observe nanoparticle reaction inside the body

Researchers at North Carolina State University have developed a method for predicting the ways nanoparticles will interact with biological systems - including the human body. Their work could have implications for improved human and environmental safety in the handling of nanomaterials, as well as applications for drug delivery.

16 Aug 2010

NIEHS procures Provantis preclinical software solution for National Toxicology Program studies

Instem, a leading provider of early drug development software solutions, announced today that the National Institute of Environmental Health Sciences has purchased the Provantis® preclinical software solution to support the collection, management and maintenance of the reproductive, perinatal and developmental National Toxicology Program studies. These studies are done predominantly at contractor laboratories at various sites throughout the United States.

13 Aug 2010

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.

13 Aug 2010

Novavax announces positive results from pre-clinical toxicology study of RSV vaccine candidate

Novavax, Inc. reported today that results from a pre-clinical toxicology study of its vaccine candidate to prevent respiratory syncytial virus, showed the vaccine to be safe and well-tolerated at all doses tested. Novavax's vaccine uses highly purified recombinant particles of RSV-F fusion protein normally found in the virus. There is currently no approved vaccine to prevent RSV infection.

13 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

K-State researcher receives grant from NIH to continue cancer research

Understanding how cancer cells communicate with each other and how to enhance their receptiveness to drug treatments is the focus of promising work by a Kansas State University researcher.Annelise Nguyen, assistant professor of toxicology in the department of diagnostic medicine and pathobiology at K-State's College of Veterinary Medicine, recently received a $370,000 grant from the National Institutes of Health to continue her cancer research.

12 Aug 2010

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Entelos receives patent for PhysioLab virtual patient technology

Entelos, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,774,182, entitled "Apparatus and Method for Validating a Computer Model." This patent was issued to Entelos for its invention of an innovative computer-implemented method for validating multiple virtual patients within a computer model. The PhysioLab virtual patient technology allows Entelos life scientists and engineers to more rapidly evaluate the safety and efficacy of new therapeutics in a diverse population of patients. This predictive power is integrated into our PhysioLab platforms, which have been used by our pharmaceutical and consumer product customers for over a decade to dramatically reduce the risk, time, and cost of product development.

11 Aug 2010

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.

10 Aug 2010

Millennium Laboratories signs agreement to assist physicians with drug monitoring services, tools

Millennium Laboratories, Inc., a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced today a national agreement with MultiPlan, the nation's leading comprehensive provider of healthcare cost management solutions. As a participating provider in the PHCS and MultiPlan Networks, Millennium Laboratories will assist participating physicians with state-of-the-art therapeutic drug monitoring services and tools.

9 Aug 2010

Forensic Laboratories' analytical test capable of detecting Ethyl Sulfate in saliva

Forensic Laboratories, a Denver-based laboratory specializing in toxicology services for drug and alcohol abuse, has announced the expansion of its oral fluid testing capabilities. The company is the first lab in the nation to develop an analytical test capable of detecting Ethyl Sulfate (EtS) in saliva, a chemical produced by the body after alcohol exposure. Forensic Laboratories' new test method will also simultaneously detect Ethyl Glucuronide (EtG).

6 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

TapImmune inks smallpox vaccine Research and Technology License Option Agreement with Mayo Clinic

TapImmune Inc. announced that it has signed a Research and Technology License Option Agreement with Mayo Clinic, Rochester, MN, for the development of a smallpox vaccine technology. Research will be conducted by Gregory Poland M.D., at Mayo Clinic, to evaluate novel peptide antigens together with TapImmune's proprietary TAP technology. TapImmune also has an exclusive Option to the smallpox vaccine technology after research studies have been completed under the terms of the agreement.

5 Aug 2010

Amplimmune collaborates with GSK to develop PD-1 targeting therapies

Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1.

5 Aug 2010

Master model to track mercury movement from original emission source to humans

University of Louisville Public Health doctoral student Caroline Chan is working to create scientific tools to help environmental policy decision makers evaluate and modify mercury emission regulations.

3 Aug 2010

Axiogenesis signs non-exclusive license agreement with iPS Academia

Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) announced that they have executed a non-exclusive agreement with iPS Academia (Kyoto, Japan) through which Axiogenesis obtains worldwide access to the extensive portfolio of induced pluripotent stem cell technology for iPSC-derived cardiomyocytes and other cell types, pioneered by Professor Shinya Yamanaka, Center for iPS Cell Research and Application at the University of Kyoto, Japan.

3 Aug 2010

High levels of lead found in Mount Isa children: Study

According to a report published in the Medical Journal of Australia (MJA) yesterday, on average one child in the Queensland mining town of Mount Isa will exceed safe lead levels every nine days. The report also claimed that not enough was done to address the problem. MP Betty Kiernan has defended the measures taken to address this serious problem.

3 Aug 2010

Toxicology News and Research

Latest Toxicology News and Research

Best practices for assessing toxicity during drug discovery process

IBCERCC to improve existing research programs for breast cancer

Researchers develop screening tool to observe nanoparticle reaction inside the body

NIEHS procures Provantis preclinical software solution for National Toxicology Program studies

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Novavax announces positive results from pre-clinical toxicology study of RSV vaccine candidate

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

K-State researcher receives grant from NIH to continue cancer research

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Entelos receives patent for PhysioLab virtual patient technology

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Millennium Laboratories signs agreement to assist physicians with drug monitoring services, tools

Forensic Laboratories' analytical test capable of detecting Ethyl Sulfate in saliva

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

TapImmune inks smallpox vaccine Research and Technology License Option Agreement with Mayo Clinic

Amplimmune collaborates with GSK to develop PD-1 targeting therapies

Master model to track mercury movement from original emission source to humans

Axiogenesis signs non-exclusive license agreement with iPS Academia

High levels of lead found in Mount Isa children: Study

Forensics And Toxicology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Toxicology News and Research

Latest Toxicology News and Research

Forensics And Toxicology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in